275 related articles for article (PubMed ID: 32187609)
21. Comparative Effectiveness of Natalizumab Versus Anti-CD20 in Highly Active Relapsing-Remitting Multiple Sclerosis After Fingolimod Withdrawal.
Rollot F; Couturier J; Casey R; Wiertlewski S; Debouverie M; Pelletier J; De Sèze J; Labauge P; Ruet A; Thouvenot E; Ciron J; Berger E; Gout O; Clavelou P; Stankoff B; Casez O; Bourre B; Zephir H; Moreau T; Lebrun-Frenay C; Maillart E; Edan G; Neau JP; Montcuquet A; Cabre P; Camdessanché JP; Defer G; Nasr HB; Maurousset A; Hankiewicz K; Pottier C; Leray E; Vukusic S; Laplaud DA
Neurotherapeutics; 2022 Mar; 19(2):476-490. PubMed ID: 35217934
[TBL] [Abstract][Full Text] [Related]
22. A multicenter, non-interventional study to evaluate the disease activity in Multiple Sclerosis after withdrawal of Natalizumab in Portugal.
Ladeira F; Braz L; Salgado P; Vaz S; Leitão L; Félix C; Correia AS; Silva AMD; Salgado V; Ferreira F; Vale J; Sá MJ; Capela C
Clin Neurol Neurosurg; 2019 Sep; 184():105390. PubMed ID: 31306895
[TBL] [Abstract][Full Text] [Related]
23. Recurrence of disease activity after repeated Natalizumab withdrawals.
Ferrè L; Moiola L; Sangalli F; Radaelli M; Barcella V; Comi G; Martinelli V
Neurol Sci; 2015 Mar; 36(3):465-7. PubMed ID: 25249399
[TBL] [Abstract][Full Text] [Related]
24. Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach.
Julian GS; Rosim RP; Carneseca EC; Rigolon J
PLoS One; 2020; 15(3):e0229768. PubMed ID: 32119696
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
[TBL] [Abstract][Full Text] [Related]
26. Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Kalincik T; Sharmin S; Roos I; Freedman MS; Atkins H; Burman J; Massey J; Sutton I; Withers B; Macdonell R; Grigg A; Torkildsen Ø; Bo L; Lehmann AK; Havrdova EK; Krasulova E; Trnený M; Kozak T; van der Walt A; Butzkueven H; McCombe P; Skibina O; Lechner-Scott J; Willekens B; Cartechini E; Ozakbas S; Alroughani R; Kuhle J; Patti F; Duquette P; Lugaresi A; Khoury SJ; Slee M; Turkoglu R; Hodgkinson S; John N; Maimone D; Sa MJ; van Pesch V; Gerlach O; Laureys G; Van Hijfte L; Karabudak R; Spitaleri D; Csepany T; Gouider R; Castillo-Triviño T; Taylor B; Sharrack B; Snowden JA; ; ; Mrabet S; Garber J; Sanchez-Menoyo JL; Aguera-Morales E; Blanco Y; Al-Asmi A; Weinstock-Guttman B; Fragoso Y; de Gans K; Kermode A;
JAMA Neurol; 2023 Jul; 80(7):702-713. PubMed ID: 37437240
[TBL] [Abstract][Full Text] [Related]
27. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom.
Spelman T; Herring WL; Zhang Y; Tempest M; Pearson I; Freudensprung U; Acosta C; Dort T; Hyde R; Havrdova E; Horakova D; Trojano M; De Luca G; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Alroughani R; Pucci E; Granella F; Lechner-Scott J; Sola P; Ferraro D; Grand'Maison F; Terzi M; Rozsa C; Boz C; Hupperts R; Van Pesch V; Oreja-Guevara C; van der Walt A; Jokubaitis VG; Kalincik T; Butzkueven H;
Pharmacoeconomics; 2022 Mar; 40(3):323-339. PubMed ID: 34921350
[TBL] [Abstract][Full Text] [Related]
28. Fingolimod for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Al Malik Y; Meftah I
Clin Neuropharmacol; 2020; 43(2):35-38. PubMed ID: 32106137
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of alemtuzumab versus fingolimod in RRMS after natalizumab cessation.
Pfeuffer S; Schmidt R; Straeten FA; Pul R; Kleinschnitz C; Wieshuber M; Lee DH; Linker RA; Doerck S; Straeten V; Windhagen S; Pawlitzki M; Aufenberg C; Lang M; Eienbroeker C; Tackenberg B; Limmroth V; Wildemann B; Haas J; Klotz L; Wiendl H; Ruck T; Meuth SG
J Neurol; 2019 Jan; 266(1):165-173. PubMed ID: 30446966
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
O'Day K; Meyer K; Stafkey-Mailey D; Watson C
J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
[TBL] [Abstract][Full Text] [Related]
31. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Zhu C; Kalincik T; Horakova D; Zhou Z; Buzzard K; Skibina O; Alroughani R; Izquierdo G; Eichau S; Kuhle J; Patti F; Grand'Maison F; Hodgkinson S; Grammond P; Lechner-Scott J; Butler E; Prat A; Girard M; Duquette P; Macdonell RAL; Weinstock-Guttman B; Ozakbas S; Slee M; Sa MJ; Van Pesch V; Barnett M; Van Wijmeersch B; Gerlach O; Prevost J; Terzi M; Boz C; Laureys G; Van Hijfte L; Kermode AG; Garber J; Yamout B; Khoury SJ; Merlo D; Monif M; Jokubaitis V; van der Walt A; Butzkueven H;
JAMA Neurol; 2023 Jul; 80(7):739-748. PubMed ID: 37273217
[TBL] [Abstract][Full Text] [Related]
32. Cost-minimization analysis of alemtuzumab compared to fingolimod and natalizumab for the treatment of active relapsing-remitting multiple sclerosis in the Netherlands.
Piena MA; Heisen M; Wormhoudt LW; Wingerden JV; Frequin STFM; Uitdehaag BMJ
J Med Econ; 2018 Oct; 21(10):968-976. PubMed ID: 29911917
[TBL] [Abstract][Full Text] [Related]
33. [Efficacy and safety of fingolimod in routine clinical practice in patients with relapsing-remitting multiple sclerosis in Spain: an intermediate analysis of the MS NEXT study].
Mallada-Frechin J; Meca-Lallana V; Barrero F; Martinez-Gines ML; Marzo-Sola ME; Ricart J; Garcia E; En Representacion de Los Investigadores Del Estudio Ms Next ERLIDEMN
Rev Neurol; 2018 Sep; 67(5):157-167. PubMed ID: 30047118
[TBL] [Abstract][Full Text] [Related]
34. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment.
Vollmer BL; Nair KV; Sillau S; Corboy JR; Vollmer T; Alvarez E
Ann Clin Transl Neurol; 2019 Feb; 6(2):252-262. PubMed ID: 30847358
[TBL] [Abstract][Full Text] [Related]
35. The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
Izquierdo G; Damas F; Páramo MD; Ruiz-Peña JL; Navarro G
PLoS One; 2017; 12(4):e0176174. PubMed ID: 28453541
[TBL] [Abstract][Full Text] [Related]
36. Effects of Natalizumab and Fingolimod on Clinical, Cognitive, and Magnetic Resonance Imaging Measures in Multiple Sclerosis.
Preziosa P; Rocca MA; Riccitelli GC; Moiola L; Storelli L; Rodegher M; Comi G; Signori A; Falini A; Filippi M
Neurotherapeutics; 2020 Jan; 17(1):208-217. PubMed ID: 31452082
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of Natalizumab Compared With Fingolimod for Relapsing-Remitting Multiple Sclerosis Treatment in Colombia.
Lasalvia P; Hernández F; Castañeda-Cardona C; Cuestas JA; Rosselli D
Value Health Reg Issues; 2020 Dec; 23():13-18. PubMed ID: 31999987
[TBL] [Abstract][Full Text] [Related]
38. Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis.
Frisell T; Forsberg L; Nordin N; Kiesel C; Alfredsson L; Askling J; Hillert J; Olsson T; Piehl F
Mult Scler; 2016 Jan; 22(1):85-93. PubMed ID: 25921036
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center.
Boziki M; Bakirtzis C; Giantzi V; Sintila SA; Kallivoulos S; Afrantou T; Nikolaidis I; Ioannidis P; Karapanayiotides T; Koutroulou I; Parissis D; Grigoriadis N
Front Neurol; 2021; 12():699844. PubMed ID: 34497577
[No Abstract] [Full Text] [Related]
40. Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies.
Sahloul O; Louapre C; Beigneux Y; Lubetzki C; Maillart E; Roux T
Mult Scler Relat Disord; 2024 May; 85():105557. PubMed ID: 38520946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
